Sagimet udates on quarter, MASH, acne progress

 Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China

Initiated first-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 being developed for acne in the U.S.

Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026

https://www.globenewswire.com/news-release/2025/08/13/3132474/0/en/Sagimet-Biosciences-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Updates.html